100 results about "Right heart ventricle" patented technology

The invention provides an intelligent auxiliary evaluation system for right ventricular systole and diastole functions of echocardiography, and aims to solve the problems of low accuracy and efficiency in right ventricular function evaluation in the prior art. The system comprises an image acquisition unit, an image processing unit, a feature extraction unit, an intelligent evaluation unit and a result output unit, and through an intelligent algorithm, especially a deep learning network DL and a convolutional neural network CNN, a feature extraction result is obtained. Key indexes such as a two-dimensional right ventricular area change fraction 2D-FAC, a right ventricular ejection fraction RVEF and tricuspid valve ring plane contraction period displacement TAPSE are automatically calculated. The system also realizes accurate evaluation of the right ventricular function through a specific CNN structure and loss function design. The system can provide rapid, accurate and non-invasive right ventricular function evaluation in clinical practice, and is helpful for improving the diagnosis and treatment effects of cardiovascular diseases.

Tricuspid valve repair devices and associated systems and methods are disclosed herein. A tricuspid valve repair device configured in accordance with embodiments of the present technology can include, for example, a coaptation member configured to be positioned between one or more native leaflets of the tricuspid valve to at least partially fill a space between the native leaflets. The tricuspid valve repair device can further include one or more fixation mechanisms for securing the coaptation member in position between the leaflets. The fixation mechanisms can include clip mechanisms, lock mechanisms, stabilization members, anchors, and / or other structures configured to engage cardiac anatomy local to or remote from the tricuspid valve, such as the native leaflets, the tricuspid valve annulus, the right ventricular outflow tract, the superior vena cava, the inferior vena cava, and so on.

The invention discloses annexin A2 (ANXA2) and application of an inhibitor thereof in diagnosis, treatment and / or prevention of pulmonary arterial hypertension. In particular discloses application of an ANXA2 inhibitor (including siRNA for silencing an ANXA2 gene, an ANXA2 antibody and a phosphorylation inhibitor) in preparation of a product for preventing and / or treating pulmonary arterial hypertension. Experiments prove that the ANXA2 inhibitor can significantly inhibit proliferation and migration of pulmonary artery smooth muscle cells, and significantly improve pulmonary arterial hypertension, pulmonary artery vascular remodeling and right ventricular hypertrophy. The ANXA2 or the Thr208 phosphorylation site of the ANXA2 protein can be used for diagnosis or auxiliary diagnosis of pulmonary arterial hypertension, or used for screening drugs for pulmonary arterial hypertension and developing new diagnosis and treatment methods and drugs. The therapeutic target and the ANXA2 inhibitor developed by the invention have wide clinical application value in the fields of diagnosis, prevention and treatment of pulmonary arterial hypertension.

The invention relates to the field of medical image segmentation, in particular to a rapid and efficient heart magnetic resonance image automatic segmentation method. Firstly, a U-Net model is improved, four times of down-sampling and up-sampling of the U-Net are expanded to five times, and the resolution of the model and the capability of capturing finer features are improved; a traditional 3 * 3 convolutional layer in the U-Net is replaced by an MSRF module, and the model is helped to extract image features on different scales, so that the network can better capture multi-level information; an scSE module is added between up-sampling and jump connection of the U-Net, and the segmentation ability of the model at the right ventricle and myocardial edges is improved; and finally, combining the cross entropy loss and the Dice loss to train an MS-UNet network so as to improve the segmentation precision of the ventricular and myocardial regions at the same time. According to the method, the heart magnetic resonance image can be quickly and accurately segmented, and the segmentation speed and precision are improved.

The invention discloses a cardiac magnetic resonance cardiac function evaluation method based on multi-task learning, and belongs to the technical field of medical image processing. The method comprises the following steps: labeling, enhancing and preprocessing cardiac magnetic resonance image data; training a multi-task learning model by using the preprocessed data, supervising a multi-task training process by introducing regional geometric consistency loss, and improving the accuracy and generalization performance of the model; inputting a to-be-evaluated heart magnetic resonance image into the trained multi-task learning model to obtain left and right ventricular intima segmentation results in a heart anatomical structure, a left ventricular myocardial segmentation result and a right ventricular insertion point and a left ventricular central point in a heart key point position; further calculating the ventricular volume to obtain left and right ventricular ejection fractions; calculating the thickness of each segment of the left ventricular myocardium; and outputting a cardiac function evaluation result. According to the method, the accuracy and generalization performance of the model are improved, and the problems that a traditional method is low in precision and long in analysis time consumption are solved.

The invention belongs to the technical field of medical image segmentation, and discloses a medical image segmentation method, system and device based on a twin network and multi-view fusion, and a medium, and the method comprises the steps: obtaining the sequence slice data of a heart magnetic resonance image; inputting the sequence slice data into a medical image segmentation model for image segmentation to obtain a segmentation result corresponding to each slice data; the segmentation result comprises segmentation masks of the left ventricle, the right ventricle and the cardiac muscle; the medical image segmentation model is constructed based on an encoder-decoder network, an encoder comprises a plurality of encoder branches with the same structure and unshared weights, and the encoder branches comprise an original slice image encoding branch, a region constraint slice encoder branch, a high-frequency information encoding branch and a low-frequency information encoding branch. The decoder comprises a plurality of decoding blocks with bottleneck structures. According to the invention, the accuracy and efficiency of segmentation are improved, and the robustness and applicability of the model are enhanced.

The invention relates to the technical field of biological medicines, in particular to a pharmaceutical composition and application thereof in preparation of a medicine for treating the heart-lung qi deficiency type pulmonary heart disease. The pharmaceutical composition consists of 21-27 parts of astragalus membranaceus, 13-17 parts of semen lepidii, 7-10 parts of cassia twig, 21-27 parts of ligusticum wallichii, 7-10 parts of rhizoma alismatis, 5-7 parts of platycodon grandiflorum and 2-4 parts of Chinese dates. Compared with the prior art, the cassia twig is adopted to replace fructus psoraleae in an original formula, and meanwhile, the medicinal material specifications of the fried semen descurainiae, the raw ligusticum wallichii and the salted rhizoma alismatis are preferably selected. The invention also provides three preparation methods of the pharmaceutical composition, namely a water extraction and alcohol precipitation method, an alcohol extraction and water extraction combined method and a crushing and mixing method. Experimental results show that the pharmaceutical composition has remarkable effects on improving heart functions, lung functions, blood-gas indexes, right ventricular hypertrophy and the like of pulmonary heart disease model animals, meanwhile, the hepatotoxicity risk of fructus psoraleae is avoided, and the pharmaceutical composition has a good clinical application prospect.

In some aspects, the disclosure relates to GDF / BMP antagonists and methods of using GDF3 / BMP antagonists to treat, prevent, or reduce the progression rate and / or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and / or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF / BMP antagonist to treat, prevent, or reduce the progression rate and / or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF / BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

An introductory lead system can include a first implantable lead having a first electrode and a second implantable lead having a second electrode guided to an implant site by the first implantable lead. The second electrode can be implanted in a patient's heart at the same implant site as the first electrode or at a second implant site. The introductory lead system can be delivered to one or more implant sites using various methods, including at the Koch triangle for ventricular free wall to atrium (VfA) therapy, at the right ventricular septal wall for dual bundle branch pacing, or in the coronary vasculature for left-sided sensing and pacing.

The invention relates to a simulator comprising a flexible simulation chamber simulating a living body chamber, the flexible simulation chamber having at least one opening; a valve comprising a valve leaflet; a papillary muscle entity model; and chordae tendineae connecting the papillary muscle entity model and the valve leaflets; at least one valve arm extends through the flexible simulation cavity, so that the far end of the valve arm is arranged in the flexible simulation cavity, the near end of the valve arm is arranged outside the flexible simulation cavity, the far end of the valve arm is fixed relative to the papillary muscle entity model, and the position of the far end of the valve arm can be controlled from the near end; and a control device for controlling the simulation process. Such a simulator allows for precise simulation of motion of a living body chamber, such as the left ventricle or the right ventricle of a human heart, in which case precise rotation and / or other motion of the chamber during a pulsation can be simulated.

The present invention provides novel 4-methylsulfone-substituted piperidine / urea compounds useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and / or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds, as well as methods for the treatment of DCM and other forms of heart disease, are described.

Illustrative devices and methods may provide cardiac resynchronization therapy (CRT) that utilizes instantaneous CRT settings to mitigate right ventricular load during implementation of the CRT. The aggressiveness of the instantaneous CRT setting may be increased until the target CRT setting is reached. Further, the transient CRT setting may reduce aggressiveness in response to ventricular degradation.

This invention provides a wearable myocardial oxygenation monitoring device based on optical path arrangement, comprising a detection component and a control component integrated into a flexible layer. The detection component includes multi-wavelength light sources arranged at an angle of 5° to 20° to the sagittal plane of the human body, detection components partitioned according to coordinate systems of 180° to 240° and 315° to 45°, and diagonally arranged electrocardiogram electrodes. The light sources correspond to the anatomical structure of the anterior interventricular groove of the heart. The control component achieves synchronous signal acquisition and processing via an FPC circuit board. Through precise anatomical positioning, partitioned detection, and flexible fit design, this invention solves the problem of difficulty in distinguishing the functional differences between the left and right ventricles in existing technologies. An adaptive light intensity modulation mechanism based on BMI ensures the optimal balance between signal quality and energy efficiency for different body types. Multi-data fusion enhances the early warning sensitivity of myocardial ischemia, making it suitable for people of different body types and providing a reliable tool for early screening of coronary heart disease.

A first ventricular surface anchor can be placed against a first right ventricular surface, wherein the first ventricular surface anchor is connected to a first tension member. A first tension anchor against a tension anchor surface of a heart, wherein the first tension anchor is connected to a second tension member. The first tension member connected to the first ventricular surface anchor can extend towards the second tension member connected to the first tension anchor. The first tension member and the second tension member can draw the first right ventricular surface toward the first tension anchor. The surface anchor can include a nitinol frame forming an outer perimeter. The nitinol frame can have an austenite state in a deployed configuration when a temperature of the nitinol frame is body temperature. The surface anchor can also include a grommet comprising a distal tubular portion connected to a proximal finger portion.

The utility model discloses a percutaneous circulation auxiliary device. The percutaneous circulation auxiliary device comprises an intervention catheter and a diaphragm pump. The intervention catheter is provided with at least one blood inlet and at least one blood outlet, the blood inlet and the blood outlet are both one-way valves and are both in one-way conduction, and the diaphragm pump comprises a blood cavity separated by a flexible diaphragm and a driving liquid cavity used for charging and discharging liquid. When in use, the device is communicated with a liquid charging and discharging control device, is mainly used for assisting blood pumping of the right ventricle, can be placed into the right ventricle through femoral veins, assists the heart in doing work, and increases cardiac output; the utility model relates to a pulsating pump which can pump blood according to systole and diastole of the heart. The device is simple in structure and low in manufacturing cost, and has a good application prospect.

In some instances, a computing device can determine information corresponding to a data structure and indicating delays associated with atrial leads, left ventricular (LV) leads, and right ventricular (RV) leads, based on one or more input variables. The computing device can determine multiple personalized characteristics based on the information corresponding to the data structure. The computing device can receive multiple second sets of electrical measurements from multiple measuring electrodes, based on the multiple personalized characteristics, indicating a second electrical signal applied to the patient's heart. The computing device can use a first set of electrical measurements (e.g., raw measurements) and the multiple second sets of electrical measurements to determine a cardiac resynchronization index (CRI) value. The computing device can generate a graphical representation based on the populated data structure and display the graphical representation.

A first ventricular surface anchor can be placed against a first right ventricular surface, wherein the first ventricular surface anchor is connected to a first tension member. A first tension anchor against a tension anchor surface of a heart, wherein the first tension anchor is connected to a second tension member. The first tension member connected to the first ventricular surface anchor can extend towards the second tension member connected to the first tension anchor. The first tension member and the second tension member can draw the first right ventricular surface toward the first tension anchor. The surface anchor can include a nitinol frame forming an outer perimeter. The nitinol frame can have an austenite state in a deployed configuration when a temperature of the nitinol frame is body temperature. The surface anchor can also include a grommet comprising a distal tubular portion connected to a proximal finger portion.

The present invention relates to an apparatus and a method for dividing a membranous spacing. The method comprises the following steps: segmenting a left ventricular outflow tract LVOT of a heart in a 3D image data set; determining wall thickness information indicating spaced wall thicknesses at different locations of a portion of the segmented LVOT oriented toward the right ventricle and the right atrium; mapping the determined wall thickness information onto a surface of the portion of the segmented LVOT; and segmenting the membranous spacing in the 3D image dataset based on the mapped wall thickness information.

This invention relates to the field of biomedical technology, specifically to the application of PTPRM in the treatment and / or prevention of septic cardiomyopathy. This application found that the expression level of PTPRM was significantly reduced in the cardiac tissue of a CLP model, and further verified that overexpression of PTPRM significantly improved the survival rate of the CLP model. Furthermore, the reduction in PAT caused by CLP modeling, as well as the increases in RVDFW, RVSFW, LVSFW, LVDFW, IVS-s, and IVS-d, were also improved. In addition, overexpression of PTPRM can also reduce the expression level of cardiac troponin (cTNT) and right ventricular wall thickness. Therefore, PTPRM can be used as a target for the treatment of septic cardiomyopathy.

The invention discloses application of ellagic acid to prevention of heart injury caused by long-term diving. A medicine for preventing heart injury caused by long-term diving is a medicine composition taking ellagic acid as a unique active ingredient or containing ellagic acid. According to the application of ellagic acid in prevention of heart injury caused by long-term phreatic water, animal in-vivo experiment results show that the morbidity of myocardial infarction of a long-term simulated phreatic water rat model is reduced to 23.8% from 44.8% through ellagic acid administration, the infarction area is remarkably reduced to 4.6 + / -3.3% from 14.9 + / -7.7%, the right ventricular hypertrophy index is reduced to 23.3 + / -6.5% from 34.5 + / -12.2%, and the curative effect is remarkable. The ellagic acid can effectively prevent rat heart injury caused by long-term diving. Therefore, ellagic acid has a good application prospect in prevention of heart injury caused by long-term diving.

A method of pacing a heart includes implanting a subcutaneously implantable device on a xiphoid process and / or a sternum of a patient. The subcutaneously implantable device includes a housing, a prong extending away from the housing, and a first electrode at a distal end of the prong. The method further includes contacting a Manicka Zone of Pacing on an anterior surface of the heart with the first electrode on the distal end of the prong. The Manicka Zone of Pacing is defined as an area of the heart extending 3 centimeters (1.1811 inches) laterally outward from either side of a left anterior descending artery of the heart. A pacing signal is delivered to the Manicka Zone of Pacing of the heart through the first electrode. A right ventricle and a left ventricle of the heart are synchronously paced with the pacing signal received in the Manicka Zone of Pacing.

The application discloses a ventricular premature beat type determination method, device, equipment and medium, and the method comprises the following steps: performing feature wave identification on a periodic waveform in a to-be-identified waveform; if no feature wave exists in the periodic waveform, determining a positive wave peak value and a corresponding positive wave peak time point, and a negative wave peak value and a corresponding negative wave peak time point according to a voltage corresponding to each time point in the periodic waveform; for any time point, if a comparison result of the voltage corresponding to the time point and the positive wave peak value and the negative wave peak value satisfies a first preset condition, and a comparison result of the time point and the positive wave peak time point and the negative wave peak time point satisfies a second preset condition, then the waveform between the time point and the wave peak time point is determined as a target waveform; and according to a position of the target waveform in the periodic waveform, left ventricular premature beat or right ventricular premature beat is determined. The detection and judgment of the ventricular premature beat type are automatically realized, and the detection efficiency is improved.

The invention discloses application of scopalactone in treatment of pulmonary arterial hypertension, and relates to the technical field of medicinal chemistry. The scoparone is applied to preparation of the medicine for treating pulmonary arterial hypertension. The medicine comprises scopalactone, a pharmaceutically acceptable carrier, a diluent and an excipient, the medicine further comprises other medicines for treating the pulmonary arterial hypertension, and the other medicines for treating the pulmonary arterial hypertension are selected from a prostacyclin medicine, an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor. The scopalactone is applied to preparation of the medicine for treating pulmonary arterial hypertension, right heart insufficiency caused by hypoxia can be remarkably reversed, and the right heart function is effectively improved by reducing the transverse diameter of the right ventricle and the transverse diameter of the right atrium and improving the indexes such as tricuspid valve ring plane contraction displacement; the average pulmonary arterial pressure and right ventricular systolic pressure can be obviously reduced, and hemodynamic parameters are improved; the area and thickness of a blood vessel wall can be remarkably reduced, the blood vessel structure is improved, and pulmonary arteriole reconstruction is relieved.

The application discloses a traditional Chinese medicine composition for treating systemic lupus erythematosus (SLE) related pulmonary arterial hypertension and application, and relates to the technical field of traditional Chinese medicine, wherein the composition is prepared from pueraria, gotukola, salvia miltiorrhiza, chuanxiong, radix scrophulariae, poria cocos, wheat bran-fried atractylodes, dried tangerine or orange peel, prepared pinellia, baked licorice, immature bitter orange fruit and gotukola, and has the functions of activating blood circulation to remove blood stasis and clearing heat and resolving toxins, and is aimed at the pathogenesis of the heat-toxin blood stasis syndrome of SLE-PAH. The application further provides a preparation method of the composition. The composition can effectively reduce the pulmonary arterial pressure of a model animal, relieve right ventricular hypertrophy and pulmonary vascular remodeling, and improve the oxidation stress level in experiments. In combination with western medicine, the composition can significantly improve the exercise endurance of a patient, improve the pulmonary arterial systolic pressure and key serological indexes, and has a better curative effect than simple western medicine and good safety, thereby providing a safe and effective traditional Chinese medicine composition for treating SLE-PAH.

To provide ultrasonic diagnostic equipment which has high general versatility and practicality in a general practice and which can more reliably make diagnoses of diseases such as cardiac amyloidosis, a medical information service system, and a method and a program for aiding a cardiac amyloidosis diagnosis.SOLUTION: Ultrasonic diagnostic equipment 5 comprises a determination part 54 that determines whether or not cardiac amyloidosis is developed, on the basis of at least one of left ventricular posterior wall thickness d1 on the rear side of the left ventricle in a view from an ultrasound probe 50 and right ventricular anterior wall thickness d2 in front of the sinus of Valsalva in a view from the ultrasound probe 50, in a parasternal long-axis section image of echocardiography.SELECTED DRAWING: Figure 5

The present invention is a high resolution, multi-function, conformal electronics device generally having a flexible and stretchable, high-density electrode array, integrated with a catheter (e.g., balloon catheter) for mapping, ablating, pacing and sensing of cardia tissue associated with heart arrhythmias. The active sensing electrode array can acquire diagnostic information including electrical (e.g., electrograms), mechanical (e.g., strain measurements), impedance (e.g., resistance), metabolic (e.g., pH or NADH measurement) from the underlying heart tissue surface with which it is in contact. The electrode array may be designed to be of various sizes and shapes to conform to the targeted cardiac tissue architecture (e.g. atrial, ventricle, right ventricular outflow tract, coronary sinus, pulmonary veins, etc.) corresponding to the specific type of cardiac arrhythmia. The present invention can precisely locate the source of arrhythmia as described above and deliver therapy from the same electrode array. This is achieved using a capacitive sensing electrode array that can not only monitor but also deliver electrical stimulation.

The present invention proposes a hypertrophic obstructive cardiomyopathy ablation device, which includes an adjustable bend sheath assembly, a mapping catheter, an ablation needle assembly, and an ultrasound assembly. The mapping catheter is inserted into the adjustable bend sheath assembly and can be moved along the axial direction of the adjustable bend sheath assembly to the distal end of the adjustable bend sheath assembly to exit. The mapping catheter is used to map the heart, and the ablation needle assembly is used to chemically ablate the hypertrophic portion of the ventricular septum of the right ventricle. The ultrasound assembly can be moved to the distal end of the adjustable bend sheath assembly to exit, and the ultrasound assembly is used to monitor the position of the ablation needle assembly. The hypertrophic obstructive cardiomyopathy ablation device integrates the ultrasound assembly, the ablation needle assembly, and the mapping catheter. Under the real-time image guidance of the ultrasound assembly, the ablation needle assembly is controlled to chemically ablate the hypertrophic portion of the myocardium, ensuring the accuracy of the ablation position and the ablation depth. Under the premise of ablation safety, alcohol ablation is given to cause myocardial necrosis in the deep layer of the ventricular septum to relieve the obstruction.

This invention discloses an intraperitoneal balloon-assisted pacing implant kit, comprising: a guiding component, a dilation catheter component, and an inflation / deflation component. The guiding component includes a first guidewire, a portion of which is located inside the pericardial cavity of the target heart. The dilation catheter component includes a main tube and a balloon. The main tube has parallel guiding and air intake channels. The first guidewire is slidably connected within the guiding channels, guiding the main tube into the body. The balloon is positioned on the main tube and connected to the air intake channel. The main tube has a groove along its axial direction. Guided by the first guidewire, the balloon is embedded in the pericardial cavity of the target heart. Air is introduced through the air intake channel, causing the balloon to extend along the groove and surround the outside of the ventricle. The inflation / deflation component is connected to the balloon. With the support of ECG gating technology, the balloon expands during cardiac systole and contracts during diastole within the pericardial cavity, thereby compressing the left and right ventricles during cardiac systole.

The application provides application of levosulpiride in preparation of a medicine for treating pulmonary arterial hypertension, and the medicine comprises levosulpiride as an active ingredient. Through a pulmonary arterial hypertension model of a rat, the application gives an intervention treatment of levosulpiride, and the effect of levosulpiride on pulmonary vessels is determined: the levosulpiride can reduce the mean pulmonary arterial pressure of a pulmonary arterial hypertension rat, reduce pulmonary vascular resistance, and improve right ventricle and pulmonary vessel remodeling, thereby providing a strategy for developing the medicine for treating the pulmonary arterial hypertension.